VRCA Verrica Pharmaceuticals Inc.
$3.48▲ +0.29%
Healthcare
Other
Volume 22.2K
Avg Volume (10D) 63.3K
Key Metrics & Fundamentals
Market Cap
$59.78M
P/E Ratio
–
Div Yield
0.00%
52W Range
3.28 - 9.82
% vs 50 MA
-22.11%
% vs 200 MA
-38.44%
RSI-14
36.6
MACD Histogram
+0.0000
Beta (1Y vs SPY)
2.01
Free Cash Flow
-$9.28M
Gross Rev
$5.86M
Gross Profit
$4.98M
EBITDA
-$11.08M
COGS
$878,000
Operating Exp
$16.38M
Operating Income
-$11.40M
EBIT
-$11.40M
Pretax Income
-$13.15M
Net Income
-$13.15M
EPS (Diluted)
-0.62
Price & Volume History
Loading chart…
Recent News
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
GlobeNewswire · Oct 22, 2026 8:00 AM ET
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
GlobeNewswire · Sep 30, 2026 8:00 AM ET
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
GlobeNewswire · Sep 10, 2026 8:05 AM ET
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 8, 2026 8:00 AM ET
Verrica completes enrolment in Phase III trial of Ycanth
Hospital Management · Aug 28, 2026 6:47 AM ET
Lake Street Initiates Verrica Pharmaceuticals at Buy With $9 Price Target
MT Newswires · Aug 28, 2026 6:27 AM ET
Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
GlobeNewswire · Aug 27, 2026 8:00 AM ET
Verrica Pharmaceuticals Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026 3:04 PM ET
Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue Estimates
Zacks · Aug 6, 2026 7:10 PM ET
Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results
GlobeNewswire · Aug 6, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See VRCA's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.